Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Research and development - MRTP

Sales, general and administrative

Impairment of intangible assets

Depreciation

Amortization

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

22nd Century Group

22nd Century Group, Inc. is a biotechnology company, which develops disruptive plant-based solutions the for life science, consumer product, and pharmaceutical markets. It focuses on technologies that alter the level of nicotine in tobacco plants and the level of cannabinoids in hemp or cannabis plants through genetic engineering, gene-editing, and modern plant breeding techniques. The company was founded on September 12, 2005 and is headquartered in Buffalo, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

22nd Century Group advances VLN and GVB units towards profitability

22nd Century Group's Q4 2022 earnings call highlighted progress in VLN tobacco and GVB hemp/cannabis units, with plans for multi-state launches and cash positive operations in 2024. Despite challenges like the Grass Valley facility fire, the company remains focused on achieving profitability through revenue growth and market expansion. Key strengths include successful pilot results, volume growth, and a clear path to cash positivity for both business units.

22nd Century Group (XXII) reports strong Q1 performance and growth strategies

22nd Century Group (XXII) showcases strong performance and strategic initiatives to drive revenue growth and achieve cash positivity by 2024.
Despite challenges such as analyst inquiries and insurance impacts, the company's focus on cost efficiencies and margin improvements positions it for success.
Opportunities in revenue growth, bulk ingredient capacity expansion, and margin enhancements present promising prospects for future profitability and market growth.

22nd Century Group reports strong Q2 performance amidst operational challenges

22nd Century Group's Q2 performance showcased growth in sales but faced challenges in gross profit due to production mix shifts.
The company's proactive strategies for cost savings, brand value creation, and gross margin improvement indicate a focus on long-term sustainability.
Despite challenges like VLN rollout delays and tobacco business hurdles, opportunities in market differentiation and efficiency improvements are being pursued.

22nd Century Group pursues profitability through strategic shifts and cost management

22nd Century Group's Q4 2023 earnings call highlighted efforts to achieve profitability by reducing cash burn, focusing on VLN cigarettes for harm reduction, and exploring CMO opportunities in tobacco manufacturing. Despite challenges like decreased net sales and a negative gross profit, the company aims to reach breakeven by Q1 2025.

22nd Century Group reduces cash burn, aims for profitability by 2025

22nd Century Group's Q1 2024 performance reflects progress towards profitability, with improved financial discipline and operational efficiency.
While facing revenue challenges and legal disputes, the company's strategic initiatives and investor support position it for future growth and success.
The focus on reducing losses, strengthening the balance sheet, and expanding market presence underscores the company's commitment to long-term sustainability.

22nd Century Group reports Q2 financial turnaround and growth strategies

22nd Century Group's Q2 2024 performance reflects a notable financial turnaround and progress towards profitability.
Strategic initiatives, leadership appointments, and product strategies position the company for future growth and success.
While challenges remain in achieving cash positive operations, opportunities in market expansion and product innovation offer avenues for continued advancement.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

22nd Century Group, Inc. is a biotechnology company, which engages in the business of tobacco harm reduction, reduced nicotine tobacco, and improvement of health and wellness through plant science. It operates through the Tobacco and Hemp/Cannabis segments. The Tobacco segment manufactures branded filtered cigars and cigarettes. The Hemp/Cannabis segment focuses on the bulk ingredient distillate or isolate. The company was founded on September 12, 2005 and is headquartered in Buffalo, NY.

BUFFALO, N.Y., Oct. 26, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading agricultural biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technologies, today announced that the Company has further expanded on the previously announced launch of its VLN® reduced nicotine content cigarette products in Colorado with the addition of Arizona, Utah and New Mexico, collectively known as the “Four Corners” states.

22nd Century Group (Nasdaq: XXII) to Expand VLN® Sales in Three Additional States: Arizona, Utah and New Mexico

BUFFALO, N.Y., Oct. 18, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading agricultural biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technologies, today announced that James A. Mish, chief executive officer, will present at the LD Micro Main Event Investor Conference in Los Angeles, California on Wednesday, October 26, 2022 at 11:00 a.m. PT.

22nd Century Group (Nasdaq: XXII) to Present at LD Micro Conference on October 26

Applied DNA Sciences

American Virtual Cloud Technologies

FuboTV

Tattooed Chef

Best penny stocks to buy right now? The post Best Penny Stocks To Buy Now That CPI Is Out?

Best Penny Stocks To Buy Now That CPI Is Out? 5 For Your Watch List

Philip Morris

Turning Point Brands

The Zacks Tobacco industry players are battling strict government regulations as well as commodity cost inflation. However, focus on low-risk products bode well for Philip Morris (PM), Turning Point Brands (TPB) and 22nd Century Group (XXII).

3 Tobacco Stocks to Watch Even Amid Industry Challenges

BUFFALO, N.Y., Oct. 06, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading agricultural biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technologies, announced today that James A. Mish, Chief Executive Officer, will present and host investor meetings at the 7th Annual Dawson James Small Cap Growth Conference being held Wednesday, October 12, 2022, at the Wyndham Grand Hotel in Jupiter, Florida.

22nd Century Group (Nasdaq: XXII) to Participate in the Dawson James Small Cap Growth Conference on October 12

VLN ® cigarettes from 22 nd Century Group contain 95% less nicotine than conventional cigarettes , greatly reducing nicotine consumption to help smokers smoke less ; support State and FDA goals of reducing tobacco harm

First Cigarette Authorized by FDA to “Help You Smoke Less” Now Available Across Colorado

BUFFALO, N.Y., Oct. 03, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading agricultural biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technologies, today announced that the Company has added Creager Mercantile as a distribution partner to expand availability and support for its VLN® reduced nicotine content cigarette products in the state of Colorado.

22nd Century Group (Nasdaq: XXII) Expands VLN® Distributor Network with the Addition of Specialty Distributor Creager Mercantile

BUFFALO, N.Y., Sept. 20, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading agricultural biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technologies, today announced that starting in September the Company will initiate placement for VLN® reduced nicotine cigarettes in thousands of accounts across Colorado with Eagle Rock Distributing Company , a wholesale partner of Anheuser-Busch. The partnerships will bring 22nd Century's proprietary VLN® brand premium tobacco cigarettes to new, regional and national chains, and independent accounts statewide. VLN® smokes, smells, and tastes like a cigarette but contains approximately 95% less nicotine than conventional cigarettes, a level shown to be non-addictive. As noted on the packaging, VLN® is the only cigarette in the world purposefully designed to “Help You Smoke Less.”

22nd Century Group (Nasdaq: XXII) Partners With Eagle Rock Distributing Company to Place VLN® in Thousands of Retail Locations Across Colorado

Pioneer Entertainment Executive to Extend Digital Media Expertise to Company's Mission in Tobacco Harm Reduction and Raise Profile in Hemp/Cannabis Industry Pioneer Entertainment Executive to Extend Digital Media Expertise to Company's Mission in Tobacco Harm Reduction and Raise Profile in Hemp/Cannabis Industry

22nd Century Group (Nasdaq: XXII) Appoints Accomplished Media Executive Lucille S. Salhany to Its Board

BUFFALO, N.Y., Sept. 07, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading agricultural biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technologies, today announced changes in its management team as the Company accelerates growth in its reduced nicotine content tobacco business. The Company announced that Michael Zercher, President and Chief Operating Officer, will depart the Company effective September 30, 2022. John Miller, who leads 22nd Century's tobacco business team, will assume the tobacco-related duties of the Chief Operating Officer's role, while Chief Executive Officer James A. Mish will assume the title of Corporate President.

22nd Century Group (Nasdaq: XXII) Announces Management Updates and Departure of Chief Operating Officer

BUFFALO, N.Y., Sept. 07, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading agricultural biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technologies, today announced that in September the Company will expand Illinois sales of VLN® to additional stores plus launch in the state of Colorado with both current and new distribution partners. 22nd Century's proprietary VLN® brand premium tobacco cigarettes smoke, smell, and taste like cigarettes but contain approximately 95% less nicotine than conventional cigarettes, a level shown to be non-addictive. As noted on the packaging, VLN® is the only cigarette in the world purposefully designed to “help you smoke less.”

22nd Century Group (Nasdaq: XXII) Launches VLN® Reduced Nicotine Content Cigarettes in Colorado with Circle K, Smoker Friendly and New Distribution Points

VLN® King and VLN ® Menthol King is the Most Important Innovation in the Cigarette Category in Decades

22nd Century Group (Nasdaq: XXII) VLN® Reduced Nicotine Content Cigarettes Awarded Best New Product by Convenience Store News

Celebrates the Launch and Accelerated Expansion of VLN®, the Only Combustible Cigarettes Authorized by the FDA That “Helps You Smoke Less”

22nd Century Group (Nasdaq: XXII) to Ring the Nasdaq Stock Market Closing Bell

22nd Century Group, Inc. (NASDAQ:XXII ) Q2 2022 Earnings Conference Call August 9, 2022 10:00 AM ET Company Participants Joe Schepers - Vice President of Communications & Investor Relations Jim Mish - Chief Executive Officer John Miller - President of Tobacco Business Hugh Kinsman - Chief Financial Officer Conference Call Participants Vivien Azer - Cowen Aaron Grey - Alliance Global Partners Brian Wright - Roth Capital Partners Jim McIlree - Dawson James Alex Berman - Craig-Hallum Capital Group Operator Welcome to the 22nd Century Group's Second Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode and the floor will be opened for questions following management's prepared remarks.

22nd Century Group, Inc. (XXII) CEO Jim Mish on Q2 2022 Results - Earnings Call Transcript

22nd Century (XXII) delivered earnings and revenue surprises of -20% and 18.83%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

22nd Century Group (XXII) Reports Q2 Loss, Tops Revenue Estimates

BUFFALO, N.Y., Aug. 09, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading agricultural biotechnology company dedicated to improving human health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technologies, today reported results for the second quarter ended June 30, 2022, and provided an update on recent business highlights. The Company will host a live audio webcast today at 10:00 a.m. ET.

22nd Century Group (Nasdaq: XXII) Reports Business Highlights and Financial Results for the Second Quarter 2022

22nd Century (XXII) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

22nd Century (XXII) Upgraded to Strong Buy: Here's What You Should Know

22nd Century (XXII) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate 22nd Century Group (XXII) to Report a Decline in Earnings: What to Look Out for

22nd Century (XXII) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

22nd Century (XXII) Could Find Support Soon, Here's Why You Should Buy the Stock Now

BUFFALO, N.Y., July 27, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading agricultural biotechnology company dedicated to improving human health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technologies, will host a live webcast on Tuesday, August 9, 2022, at 10:00 AM ET to discuss its 2022 second quarter results, which are to be reported in a press release at 6:00 AM ET the same day.

22nd Century Group (Nasdaq: XXII) to Announce Second Quarter 2022 Results on August 9, 2022

Clever Leaves Holdings Inc

SNDL Inc.

Alan Sumler discusses his long cannabis positions and investing through a medical and historical lens. A rare opinion - Positive on Canada!

Everyone Says Sell Your Cannabis Stocks! I See It Differently (Podcast Transcript)

The biotechnology company is working hard to get up to speed, but it risks running out of highway.

22nd Century Group's Road to Cannabis May Have Some Potholes

Evofem Biosciences Inc

aTyr Pharma

Analysts say these are penny stocks to buy, do you agree? The post Best Penny Stocks to Buy Now According To 3 Top Analysts appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks to Buy Now According To 3 Top Analysts

BUFFALO, N.Y., July 21, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading agricultural biotechnology company dedicated to improving human health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technologies, announced that it has entered into definitive agreements with several institutional investors for the purchase and sale of 17,073,175 shares of its common stock at a purchase price of $2.05 per share in a registered direct offering priced above market under Nasdaq rules. The Company also agreed to issue to the investors unregistered warrants to purchase up to 17,073,175 shares of common stock. The warrants have an exercise price of $2.05 per share, are immediately exercisable and will expire five years following the date of issuance. The closing of the offering is expected to occur on or about July 25, 2022, subject to the satisfaction of customary closing conditions.

22nd Century Group (Nasdaq: XXII) Strengthens Balance Sheet to Accelerate the Expansion of VLN Launch

BUFFALO, N.Y., July 21, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), leading agricultural biotechnology company dedicated to improving human health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technologies, today announced that it has entered into definitive agreements with institutional investors for the purchase and sale of 17,073,175 shares of its common stock at a purchase price of $2.05 per share in a registered direct offering priced above market under Nasdaq rules. The Company also agreed to issue to the investors unregistered warrants to purchase up to 17,073,175 shares of common stock. The warrants have an exercise price of $2.05 per share, are immediately exercisable and will expire five years following the date of issuance. The closing of the offering is expected to occur on or about July 25, 2022, subject to the satisfaction of customary closing conditions.

News for 22nd Century Group Stock (XXII)